256 related articles for article (PubMed ID: 10918426)
1. Tacrolimus (FK506) and methotrexate as prophylaxis for acute graft-versus-host disease in pediatric allogeneic stem cell transplantation.
Yanik G; Levine JE; Ratanatharathorn V; Dunn R; Ferrara J; Hutchinson RJ
Bone Marrow Transplant; 2000 Jul; 26(2):161-7. PubMed ID: 10918426
[TBL] [Abstract][Full Text] [Related]
2. The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis.
Devine SM; Geller RB; Lin LB; Dix SP; Holland HK; Maurer D; O'Toole K; Keller J; Connaghan DG; Heffner LT; Hillyer CD; Rodey GE; Winton EF; Maher RM; Fitzsimmons WE; Wingard JR
Biol Blood Marrow Transplant; 1997 Apr; 3(1):25-33. PubMed ID: 9209738
[TBL] [Abstract][Full Text] [Related]
3. Tacrolimus as monotherapy or combined with minidose methotrexate for graft-versus-host disease prophylaxis after allogeneic peripheral blood stem cell transplantation: long-term outcomes.
Uberti JP; Ayash L; Braun T; Reynolds C; Silver S; Ratanatharathorn V
Bone Marrow Transplant; 2004 Sep; 34(5):425-31. PubMed ID: 15273705
[TBL] [Abstract][Full Text] [Related]
4. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation.
Cutler C; Kim HT; Hochberg E; Ho V; Alyea E; Lee SJ; Fisher DC; Miklos D; Levin J; Sonis S; Soiffer RJ; Antin JH
Biol Blood Marrow Transplant; 2004 May; 10(5):328-36. PubMed ID: 15111932
[TBL] [Abstract][Full Text] [Related]
5. Tacrolimus and methotrexate for the prophylaxis of acute graft-versus-host disease in allogeneic bone marrow transplantation in patients with hematologic malignancies.
Uberti JP; Silver SM; Adams PT; Jacobson P; Scalzo A; Ratanatharathorn V
Bone Marrow Transplant; 1997 Jun; 19(12):1233-8. PubMed ID: 9208118
[TBL] [Abstract][Full Text] [Related]
6. [Prophylaxis with FK-506 for graft-versus-host disease after transplantation of bone marrow from unrelated donors].
Hamazaki T; Yagi K; Inoue M; Sakata N; Okamura T; Yasui M; Sasabe M; Kishimoto T; Inoue A; Kawa K
Rinsho Ketsueki; 2000 May; 41(5):430-6. PubMed ID: 10879106
[TBL] [Abstract][Full Text] [Related]
7. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation.
Przepiorka D; Khouri I; Ippoliti C; Ueno NT; Mehra R; Körbling M; Giralt S; Gajewski J; Fischer H; Donato M; Cleary K; Claxton D; Chan KW; Braunschweig I; van Besien K; Andersson BS; Anderlini P; Champlin R
Bone Marrow Transplant; 1999 Oct; 24(7):763-8. PubMed ID: 10516680
[TBL] [Abstract][Full Text] [Related]
8. Tacrolimus for prevention of graft-versus-host disease after mismatched unrelated donor cord blood transplantation.
Przepiorka D; Petropoulos D; Mullen CA; Danielson M; Mattewada V; Chan KW
Bone Marrow Transplant; 1999 Jun; 23(12):1291-5. PubMed ID: 10414918
[TBL] [Abstract][Full Text] [Related]
9. Tacrolimus: a new agent for the prevention of graft-versus-host disease in hematopoietic stem cell transplantation.
Jacobson P; Uberti J; Davis W; Ratanatharathorn V
Bone Marrow Transplant; 1998 Aug; 22(3):217-25. PubMed ID: 9720734
[TBL] [Abstract][Full Text] [Related]
10. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
[TBL] [Abstract][Full Text] [Related]
11. Tacrolimus with mini-methotrexate as prophylaxis for graft-versus-host disease in pediatric patients after allogeneic peripheral blood stem cell transplant or bone marrow transplant.
Sabapathy C; Gourde JA; Khan SP; Rodriguez V
J Pediatr Hematol Oncol; 2008 Dec; 30(12):945-9. PubMed ID: 19131788
[TBL] [Abstract][Full Text] [Related]
12. Tacrolimus and methotrexate for the prophylaxis of graft-versus-host disease after unrelated donor cord blood transplantation for adult patients with hematologic malignancies.
Mori T; Aisa Y; Nakazato T; Yamazaki R; Shimizu T; Mihara A; Yamane A; Ikeda Y; Okamoto S
Transplant Proc; 2007 Jun; 39(5):1615-9. PubMed ID: 17580201
[TBL] [Abstract][Full Text] [Related]
13. Tacrolimus as prophylaxis for acute graft-versus-host disease in reduced intensity cord blood transplantation for adult patients with advanced hematologic diseases.
Miyakoshi S; Kami M; Tanimoto T; Yamaguchi T; Narimatsu H; Kusumi E; Matsumura T; Takagi S; Kato D; Kishi Y; Murashige N; Yuji K; Uchida N; Masuoka K; Wake A; Taniguchi S
Transplantation; 2007 Aug; 84(3):316-22. PubMed ID: 17700155
[TBL] [Abstract][Full Text] [Related]
14. Continuous infusion cyclosporine and nifedipine to day +100 with short methotrexate and steroids as GVHD prophylaxis in unrelated donor transplants.
Liesveld J; Duerst R; Rapoport A; Constine L; Abboud C; Packman C; Wedow L; Zwetsch L; McKenna B; Linder T; Silverman W; Swift S; Rowe J; DiPersio J
Bone Marrow Transplant; 1999 Sep; 24(5):511-6. PubMed ID: 10482935
[TBL] [Abstract][Full Text] [Related]
15. Effect of early posttransplantation tacrolimus concentration on the development of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation from unrelated donors.
Mori T; Kato J; Shimizu T; Aisa Y; Nakazato T; Yamane A; Ono Y; Kunimoto H; Okamoto S
Biol Blood Marrow Transplant; 2012 Feb; 18(2):229-34. PubMed ID: 21708109
[TBL] [Abstract][Full Text] [Related]
16. Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens.
Cutler C; Li S; Kim HT; Laglenne P; Szeto KC; Hoffmeister L; Harrison MJ; Ho V; Alyea E; Lee SJ; Soiffer R; Sonis S; Antin JH
Biol Blood Marrow Transplant; 2005 May; 11(5):383-8. PubMed ID: 15846292
[TBL] [Abstract][Full Text] [Related]
17. [Unrelated donor stem cell transplantation in children: low toxicity using a GvHD-prophylaxis regimen with CSA, MTX, metronidazole,iv-immunoglobulin and ATG].
Graf Finckenstein F; Zabelina T; Dürken M; Dahlke J; Kröger N; Krüger W; Janka-Schaub G; Erttmann R; Zander AR; Kabisch H
Klin Padiatr; 2002; 214(4):206-11. PubMed ID: 12165903
[TBL] [Abstract][Full Text] [Related]
18. Sirolimus and tacrolimus as immune prophylaxis compared to cyclosporine with or without methotrexate in patients undergoing allogeneic haematopoietic stem cell transplantation for non-malignant disorders.
Ringdén O; Remberger M; Dahllöf G; Garming-Legert K; Karlsson H; Svenberg P; Uhlin M; Uzunel M; Mattsson J
Eur J Haematol; 2011 Dec; 87(6):503-9. PubMed ID: 22974354
[TBL] [Abstract][Full Text] [Related]
19. Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies.
Small TN; Young JW; Castro-Malaspina H; Prockop S; Wilton A; Heller G; Boulad F; Chiu M; Hsu K; Jakubowski A; Kernan NA; Perales MA; O'Reilly RJ; Papadopoulos EB
Biol Blood Marrow Transplant; 2007 Feb; 13(2):235-44. PubMed ID: 17241929
[TBL] [Abstract][Full Text] [Related]
20. Tacrolimus instead of cyclosporine used for prophylaxis against graft-versus-host disease improves outcome after hematopoietic stem cell transplantation from unrelated donors, but not from HLA-identical sibling donors: a nationwide survey conducted in Japan.
Yanada M; Emi N; Naoe T; Sakamaki H; Takahashi S; Hirabayashi N; Hiraoka A; Kanda Y; Tanosaki R; Okamoto S; Iwato K; Atsuta Y; Hamajima N; Tanimoto M; Kato S
Bone Marrow Transplant; 2004 Aug; 34(4):331-7. PubMed ID: 15220958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]